Generic placeholder image

Current Gene Therapy

Editor-in-Chief

ISSN (Print): 1566-5232
ISSN (Online): 1875-5631

Editorial

Gene Therapy for Rare Genetic Diseases

Author(s): Kenneth Lundstrom, Evangelia Yannaki, Janice Chou and Fawzy A. Saad*

Volume 24, Issue 1, 2024

Published on: 21 March, 2023

Page: [4 - 5] Pages: 2

DOI: 10.2174/1566523223666230320120839

Price: $65

[1]
Lundstrom K. Gene therapy cargos based on viral vector delivery. Current Gene Therapy 2023; 23(2): 111-34.
[2]
Kommareddy S, Tiwari SB, Amiji MM. Long-circulating polymeric nanovectors for tumor-selective gene delivery. Technol Cancer Res Treat 2005; 4(6): 615-25.
[3]
Tomanin R, Scarpa M. Why do we need new gene therapy viral vectors? Characteristics, limitations and future perspectives of viral vector transduction. Current Gene Therapy 2004; 4(4): 357-72.
[4]
Saad FA, Saad JF, Siciliano G, Merlini L, Angelini C. Duchenne muscular dystrophy gene therapy. Current Gene Therapy In press
[5]
Chou JY, Mansfield BC. Gene therapy for type I glycogen storage diseases. Current Gene Therapy 2007; 7(2): 79-88.
[6]
Psatha N, Georgakopoulou A, Li C, et al. Enhanced HbF reactivation by multiplex mutagenesis of thalassemic CD34+ cells in vitro and in vivo. Blood 2021; 138(17): 1540-53.
[7]
Kloess S, Kretschmer A, Stahl L, Fricke S, Koehl U. CAR-expressing natural killer cells for cancer retargeting. Transfus Med Hemother 2019; 46(1): 4-13.
[8]
Li Y, Chen J, Tsai SQ, Cheng Y. Easy-Prime: A machine learning-based prime editor design tool. Genome Biol 2021; 22(1): 235.

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy